| Gene symbol | tat | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_001802.1 (5377..7970) | dbXrefs | |
| Description | Tat | ||||
| Gene symbol | vpr | Synonyms | None | Type of gene | protein coding |
| Chromosome | - | Map location | NC_001802.1 (5105..5396) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | Vpr | ||||
| GTO ID | GTC1215 |
| Trial ID | NCT00074997 |
| Disease | HIV-1 Infection |
| Altered gene | tat|vpr |
| Therapeutic/Target gene | Target gene |
| Therapy | Ribozyme |
| Treatment | anti-HIV-1 Ribozyme [OZ1] |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Randomized Phase II, Double-Blind, Controlled Trial to Evaluate the Safety and Efficacy of Autologous CD34+ Hematopoietic Progenitor Cells Transduced With Placebo or an Anti-HIV-1 Ribozyme (OZ1) in Patients With HIV-1 Infection |
| Year | 2002 |
| Country | Australia |
| Company sponsor | Janssen-Cilag Pty Ltd |
| Other ID(s) | CR010783|OZ1-HV1-201|OTH/OZ1-INT-1 |
| Vector information | |||
|
|||
| Cohort1: OZ1 | |||||||||||
|
|||||||||||
| Cohort2: Placebo | |||||||||||
|
|||||||||||